跳至主要内容
临床试验/NCT02338323
NCT02338323已完成不适用

Compare the Renal Protective Effects of Febuxostat and Benzbromarone in Chronic Kidney Disease Patients With GFR 20-50ml/Min

Shanghai 10th People's Hospital1 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2015年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
160
试验地点
1
主要终点
Renal function

研究概览

简要总结

The purpose of this study is to determine whether febuxostat and benzbromarone could protect renal function, and which one could be better.

详细描述

Chronic kidney disease patients with hyperuricemia and glomerular filtration rate (GFR) 20-50 ml/min were treated by febuxostat or benzbromarone. Follow up the changes of serum uric acid, serum creatinine and GFR levels. Compare the effects on renal function of these two drugs.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Chronic kidney disease patients with glomerular filtration rate (GFR,20-50ml/min) who match one of the following criteria:
  • Hyperuricemia patients without gout but have cardiovascular risk and serum uric acid > 480umol/L
  • Hyperuricemia patients without gout but with serum uric acid > 540umol/L

排除标准

  • GFR<20ml/min or GFR >50ml/min
  • Liver dysfunction (Aspartate transaminase or/and alanine aminotransferase exceed 2 times of normal range)
  • Urinary tract obstruction
  • unstable angina, heart failure (stage III-IV, NYHA), new stroke, need diuretics for long-term treatment
  • Severe lung diseases or cancers
  • Pregnant woman or woman who prepare to be pregnant,nursing mothers
  • unable to sign informed consent form,or disagree with following-up

研究组 & 干预措施

Febuxostat

Experimental

take orally, 40mg per day, for 1 year

干预措施: Febuxostat (Drug)

Benzbromarone

Experimental

take orally, 50mg per day, for 1 year

干预措施: Benzbromarone (Drug)

结局指标

主要结局

Renal function

时间窗: up to 12th months

Blood test for serum uric acid and creatinine, according to equation to estimate glomerular filtration rate

次要结局

  • urine protein(3rd months, 6th months, 9th months, 12th months)
  • adverse drug reaction(1st month, 2nd months, 3rd months, 6th months, 9th months, 12th months)

研究者

发起方
Shanghai 10th People's Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Ai Peng

Chief of department of Nephrology & Rheumatology

Shanghai 10th People's Hospital

研究点 (1)

Loading locations...

相似试验